
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Specialty· May 22, 2026 · 10 min read

Manufacturing· May 22, 2026 · 15 min read
Stability out-of-trend signals that can quietly derail launch supply
By Ran Chen#CMC#Manufacturing Capacity#Regulatory

Manufacturing· May 22, 2026 · 12 min read
Tech-transfer package gaps before moving a commercial product to a second site

Biosimilars· May 13, 2026 · 4 min read
How to read FDA biosimilar interchangeability without over-reading it
By Ran Chen#Biosimilars#Interchangeability#FDA Approval

Approvals· May 10, 2026 · 4 min read
Orange Book vs Purple Book: the launch-team read that prevents bad assumptions
By Ran Chen#Orange Book#Purple Book#FDA Approval

Pipeline· May 7, 2026 · 4 min read
Accelerated approval creates commercial risk even before confirmatory failure

Generics· May 6, 2026 · 3 min read
Generic entry, ANDA, and 505(b)(2): the commercial difference
By Ran Chen#Generics#505(b)(2)#Orange Book